December 17, 2014
GREENWICH, CT and SOUTHBOROUGH, MA — Corrona, a Great Point Partners (GPP”) II portfolio company and a leader in observational data and consulting in the auto-immune field, today announced that Raymond H. Hill has been elected Executive Chairman of Corrona’s board of directors.
As President at InVentiv Health Clinical, a leading contract research organization (CRO), Mr. Hill was instrumental in driving EBITDA growth, securing key strategic partnerships, and re-positioning the company. Prior to that, as President at IMS, Mr. Hill spearheaded work in portfolio strategy, pricing and market access, launch excellence, managed markets, sales force effectiveness, and commercial outsourcing. Mr. Hill also served as the CEO of Pharmaceutical Product Development Inc.
“I am thrilled that Ray Hill will be joining the Corrona team. He is an immensely wise, talented, and experienced executive who will help us excel in many areas in coming years”, said Dr. Joel Kremer, founder and Chief Medical Officer of Corrona.
“Ray will be an invaluable resource to the company”, said Noah Rhodes, Principal at Great Point Partners. “His experience managing both clinically oriented and data oriented firms in the health care field will serve us well. We look forward to his counsel on matters relating to health care data, the use of data for pharmaceutical marketing, in satisfying post approval FDA requirements, and leveraging real world data to improve health outcomes.”
“I am excited to be leading the board and advising the team at this most interesting time in health care,” said Mr. Hill. “Corrona is doing innovative work in real world patient and clinical data for autoimmune diseases. With access to over 40,000 patients and 10 years of longitudinal data, Corrona is very well positioned to help biopharmaceutical companies understand how their drugs are used and how to optimize outcomes in the real world.”
Corrona was founded in 2000 by leading physicians dedicated to advancing and improving the care of patients with chronic diseases. Our mission is to advance research and improve the quality of patient care through world class observational cohorts. Corrona provides data and research results to all biopharmaceutical companies with an interest in our therapeutic areas of coverage. Our data is used to assist in trial design, comparative effectiveness, patterning and to satisfy post market safety reporting. We are proud to be advised by experienced academic and clinical physicians throughout the country with a wide range of experiences. www.corrona.org.
About Great Point Partners
Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million in commitments. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $370 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, and specialty pharmaceuticals. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300 or www.gppfunds.com.